Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TRPV6 | Q9H1D0 | 7/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22418945 | 0.95 | LMNA (0.56) | LMNAALDH1A1TRPV6L3MBTL3L3MBTL1 | |
| SCHEMBL3397766 | 0.86 | HRH3 (0.61) | LMNAALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL15652459 | 0.85 | LMNA (0.71) | LMNAALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL20640316 | 0.85 | ALDH1A1 (0.69) | LMNAALDH1A1L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL10690328 | 0.84 | LMNA (0.80) | LMNAALDH1A1HRH3KDM4ESIGMAR1 | |
| SCHEMBL24064074 | 0.82 | POLB (0.56) | ALDH1A1TRPV6L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL12688022 | 0.82 | KDM4E (0.56) | ALDH1A1TRPV6L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL4797625 | 0.81 | SIGMAR1 (0.69) | LMNATRPV6TSHRSIGMAR1 | |
| SCHEMBL22430869 | 0.81 | ALDH1A1 (0.55) | ALDH1A1TRPV6L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL14058769 | 0.79 | L3MBTL3 (0.53) | ALDH1A1TRPV6L3MBTL3L3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101981036-B | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2013-09-04 | — | — | CN | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| CN-101981036-A | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2011-02-23 | — | — | CN | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | LMNA 3429/4885ALDH1A1 1389/4885TRPV6 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.